Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (33)
Vincent Jachiet, Pierre Fenaux, Anna Sevoyan, Yervand Hakobyan, Lionel Ades, Olivier Fain & Arsène Mekinian. (2021) Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes. Hemato 2:2, pages 329-346.
Crossref
Crossref
Jiaxiu Yin, Xinxin Li, Zaili Zhang, Xiaohua Luo, Li Wang & Lin Liu. (2018) SPAG6 silencing induces apoptosis in the myelodysplastic syndrome cell line SKM‑1 via the PTEN/PI3K/AKT signaling pathway in vitro and in vivo. International Journal of Oncology.
Crossref
Crossref
Jenna Williams, Nicole H. Heppel, Bethan Britt-Compton, Julia W. Grimstead, Rhiannon E. Jones, Sudhir Tauro, David T. Bowen, Steven Knapper, Michael Groves, Robert K. Hills, Chris Pepper, Duncan M. Baird & Chris Fegan. (2017)
Telomere length is an independent prognostic marker in MDS but not in
de novo
AML
. British Journal of Haematology 178:2, pages 240-249.
Crossref
Crossref
Qing Zeng, Jing Shu, Qi Hu, Shao-Hong Zhou, Yi-Ming Qian, Ming-Hui Hu, Ling-Yan Hu, Yu-Guang Wang, Yong-Ming Zhou & Jia-Hui Lu. (2016) Apoptosis in human myelodysplastic syndrome CD34+ cells is modulated by the upregulation of TLRs and histone H4 acetylation via a β-arrestin 1 dependent mechanism. Experimental Cell Research 340:1, pages 22-31.
Crossref
Crossref
Alexandra Helbo, Marianne Treppendahl, Derya Aslan, Konstantinos Dimopoulos, Cecilie Nandrup-Bus, Mette Holm, Mette Andersen, Gangning Liang, Lasse Kristensen & Kirsten Grønbæk. (2015) Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients. Genes 6:4, pages 977-990.
Crossref
Crossref
Martha L. Arellano, Gautam Borthakur, Mark Berger, Jill Luer & Azra Raza. (2014) A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. Clinical Lymphoma Myeloma and Leukemia 14:6, pages 534-539.
Crossref
Crossref
Matheus Rodrigues Lopes, Fabiola Traina, Paula de Melo Campos, João Kleber Novais Pereira, João Agostinho Machado-Neto, Helymar da Costa Machado, Simone Cristina Olenscki Gilli, Sara Teresinha Olalla Saad & Patricia Favaro. (2013) IL10 inversely correlates with the percentage of CD8+ cells in MDS patients. Leukemia Research 37:5, pages 541-546.
Crossref
Crossref
Kaishi Li, Meixue Yang, Gaurav Sablok, Jianping Fan & Fengfeng Zhou. (2013) Screening features to improve the class prediction of acute myeloid leukemia and myelodysplastic syndrome. Gene 512:2, pages 348-354.
Crossref
Crossref
Dominik Beck, Steve Ayers, Jianguo Wen, Miriam B Brandl, Tuan D Pham, Paul Webb, Chung-Che Chang & Xiaobo Zhou. (2011) Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. BMC Medical Genomics 4:1.
Crossref
Crossref
O. Fain, T. Braun, J. Stirnemann & P. Fenaux. (2011) Manifestations systémiques et auto-immunes des syndromes myélodysplasiques. La Revue de Médecine Interne 32:9, pages 552-559.
Crossref
Crossref
Zhang Zheng, Xu Feng, Li Xiao, Zhang Qianqiao, He Qi & Wu Lingyun. (2011) Removal of autologous activated CD4-positive T lymphocytes also results in increased colony-forming units in patients with low and intermediate-1 risk myelodysplastic syndromes. European Journal of Haematology 86:1, pages 47-56.
Crossref
Crossref
Bruno Deltreggia Benites, Fabiola Traina, Adriana da Silva Santos Duarte, Irene Gyongyver H. Lorand‐Metze, Fernando Ferreira Costa & Sara Teresinha Saad. (2010)
Increased expression of
APAF‐1
in low‐risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia
. European Journal of Haematology 84:6, pages 525-530.
Crossref
Crossref
Florian NolteWolf-K Hofmann. (2010) Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncology 6:3, pages 445-455.
Crossref
Crossref
Fiorella Alfinito, Michela Sica, Luigiana Luciano, Roberta Della Pepa, Carmela Palladino, Idalucia Ferrara, Umberto Giani, Giuseppina Ruggiero & Giuseppe Terrazzano. (2010) Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. British Journal of Haematology 148:1, pages 90-98.
Crossref
Crossref
S Boehrer, L Adès, N Tajeddine, W K Hofmann, S Kriener, G Bug, O G Ottmann, M Ruthardt, L Galluzzi, C Fouassier, M Tailler, K A Olaussen, C Gardin, V Eclache, S de Botton, S Thepot, P Fenaux & G Kroemer. (2009) Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 28:22, pages 2205-2218.
Crossref
Crossref
Wolf C. Prall, Akos Czibere, Franck Grall, Dimitrios Spentzos, Ulrich Steidl, Aristoteles Achilles Nikolaus Giagounidis, Andrea Kuendgen, Hasan Otu, Astrid Rong, Towia A. Libermann, Ulrich Germing, Norbert Gattermann, Rainer Haas & Manuel Aivado. (2009) Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome. International Journal of Hematology 89:2, pages 173-187.
Crossref
Crossref
Jean-Marie Ramirez, Olivier Schaad, Stephane Durual, Dominique Cossali, Mylène Docquier, Photis Beris, Patrick Descombes & Thomas Matthes. (2009) Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. British Journal of Haematology 144:2, pages 251-262.
Crossref
Crossref
Simone Boehrer, Lionel Adès, Lorenzo Galluzzi, Nicolas Tajeddine, Maximilien Tailler, Claude Gardin, Stéphane de Botton, Pierre Fenaux & Guido Kroemer. (2008) Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison. Biochemical Pharmacology 76:11, pages 1417-1425.
Crossref
Crossref
Rosangela Invernizzi & Erica Travaglino. (2008) Increased Apoptosis as a Mechanism of Ineffective Erythropoiesis in Myelodysplastic Syndromes. Clinical Leukemia 2:2, pages 113-120.
Crossref
Crossref
Elaine M. Sloand & Katayoun Rezvani. (2008) The Role of the Immune System in Myelodysplasia: Implications for Therapy. Seminars in Hematology 45:1, pages 39-48.
Crossref
Crossref
Daniella B. Kerbauy & H. Joachim Deeg. (2007) Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Experimental Hematology 35:11, pages 1739-1746.
Crossref
Crossref
James Edwin Thompson, Joseph Patrick Conlon, Xiaowei Yang, Patricia Vanessa Sanchez & Martin Carroll. (2007) Enhanced growth of myelodysplastic colonies in hypoxic conditions. Experimental Hematology 35:1, pages 21-31.
Crossref
Crossref
Arnold Ganser, Jakob Passweg, Michael Stadler, Christiane Dobbelstein & Eva M. Weissinger. (2007) Immunosuppressive treatment strategies in low-risk MDS. Cancer Treatment Reviews 33, pages S11-S14.
Crossref
Crossref
Ha Thanh Nishino & Chung-Che Chang. (2005) Myelodysplastic Syndromes: Clinicopathologic Features, Pathobiology, and Molecular Pathogenesis. Archives of Pathology & Laboratory Medicine 129:10, pages 1299-1310.
Crossref
Crossref
Elaine M. SloandLori MainwaringMonika FuhrerShakti RamkissoonAntonio M. RisitanoKeyvan KeyvanafarJun LuAtanu BasuA. John BarrettNeal S. Young. (2005) Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106:3, pages 841-851.
Crossref
Crossref
M.G. Alexandrakis, F.H. Passam, C.A. Pappa, J. Damilakis, G. Tsirakis, E. Kandidaki, A.M. Passam, E.N. Stathopoulos & D.S. Kyriakou. (2016) Serum Evaluation of Angiogenic Cytokines Basic Fibroblast Growth Factor, Hepatocyte Growth Factor and TNF-ALPHA in Patients with Myelodysplastic Syndromes: Correlation with Bone Marrow Microvascular Density. International Journal of Immunopathology and Pharmacology 18:2, pages 287-295.
Crossref
Crossref
Kapil Bhalla & Alan List. (2004) Histone deacetylase inhibitors in myelodysplastic syndrome. Best Practice & Research Clinical Haematology 17:4, pages 595-611.
Crossref
Crossref
Ghulam J. Mufti. (2004) Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Practice & Research Clinical Haematology 17:4, pages 543-557.
Crossref
Crossref
Xiao Li, Eileen Bryant & H. Joachim Deeg. (2004) Simultaneous Demonstration of Clonal Chromosome Abnormalities and Apoptosis in Individual Marrow Cells in Myelodysplastic Syndrome. International Journal of Hematology 80:2, pages 140-145.
Crossref
Crossref
Alison M John, N.Shaun B Thomas, Ghulam J Mufti & Rose Ann Padua. (2004) Targeted therapies in myeloid leukemia. Seminars in Cancer Biology 14:1, pages 41-62.
Crossref
Crossref
M Benesch, U Platzbecker, J Ward, H J Deeg & W Leisenring. (2003) Expression of FLIPLong and FLIPShort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 17:12, pages 2460-2466.
Crossref
Crossref
Carmine Selleri, Jaroslaw P. Maciejewski, Lucio Catalano, Patrizia Ricci, Claudia Andretta, Luigiana Luciano & Bruno Rotoli. (2002) Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia. Cancer 95:9, pages 1911-1922.
Crossref
Crossref
Carlos M. de Castro. (2002) Commentary: targeting myelodysplastic syndromes. Leukemia Research 26:8, pages 703-704.
Crossref
Crossref